Lataa...
Standard Versus Continuous Administration of Capecitabine in Metastatic Breast Cancer (GEICAM/2009-05): A Randomized, Noninferiority Phase II Trial With a Pharmacogenetic Analysis
BACKGROUND. The approved capecitabine regimen as monotherapy in metastatic breast cancer (MBC) is 1,250 mg/m(2) twice daily for 2 weeks on and 1 week off (Cint). Dose modifications are often required because of severe hand-foot syndrome (HFS). We tested a continuous regimen with a lower daily dose b...
Tallennettuna:
Julkaisussa: | Oncologist |
---|---|
Päätekijät: | , , , , , , , , , , , , , , , , , , , , , , , |
Aineistotyyppi: | Artigo |
Kieli: | Inglês |
Julkaistu: |
AlphaMed Press
2015
|
Aiheet: | |
Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4319639/ https://ncbi.nlm.nih.gov/pubmed/25601966 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2014-0379 |
Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|